Stockreport

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease

Sanofi - American Depositary Shares  (SNY) 
US:NYSE Investor Relations: sanofi.com/en/investors
PDF Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4 [Read more]